Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD
Abstract Objective Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune‐mediated disorder with aquaporin 4‐immunoglobulin G (AQP4‐IgG) in most settings. Soluble programmed death‐1 (sPD‐1) and soluble programmed death ligand 1 (sPD‐L1) play key roles in immunomodulation. We aim to assess t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.51964 |
| _version_ | 1797311737338265600 |
|---|---|
| author | Jia Liu Xi Shao Jingya Fan Ying Wang Yuanbo Cao Guojun Tan Kazuo Sugimoto Bin Li Zhen Jia |
| author_facet | Jia Liu Xi Shao Jingya Fan Ying Wang Yuanbo Cao Guojun Tan Kazuo Sugimoto Bin Li Zhen Jia |
| author_sort | Jia Liu |
| collection | DOAJ |
| description | Abstract Objective Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune‐mediated disorder with aquaporin 4‐immunoglobulin G (AQP4‐IgG) in most settings. Soluble programmed death‐1 (sPD‐1) and soluble programmed death ligand 1 (sPD‐L1) play key roles in immunomodulation. We aim to assess the association of sPD‐1 and sPD‐L1 with cytokines and their clinical significance in AQP4‐IgG (+) NMOSD. Method We measured plasma sPD‐1, sPD‐L1, and 10 cytokines levels of 66 AQP4‐IgG (+) NMOSD patients, including 40 patients in attack (attack‐NMOSD) and 26 patients in remission (remission‐NMOSD) phases, and 28 healthy controls through ultrasensitive Simoa and SP‐X platform, respectively. We also performed >2 years (median) of follow‐up after testing and analyzed the relationship between the detection index and current and future clinical parameters. Result Plasma sPD‐1 level discriminated attack‐NMOSD from remission‐NMOSD (AUC = 0.692, p = 0.009). sPD‐1 and sPD‐L1 levels positively correlated with IL‐6 (rsPD‐1 = 0.313; rsPD‐L1 = 0.508), IFN‐γ (rsPD‐1 = 0.331; rsPD‐L1 = 0.456), and TNF‐α (rsPD‐1 = 0.451; rsPD‐L1 = 0.531) expression, as well as clinical indicators, including the EDSS score (rsPD‐1 = 0.331; rsPD‐L1 = 0.402), number of attacks (rsPD‐1 = 0.431) and segments of spinal cord involvement (rsPD‐1 = 0.462; rsPD‐L1 = 0.508). The risk of relapse within 2 years after sampling was associated with higher sPD‐1/sPD‐L1 ratio in attack‐NMOSD (p = 0.022; Exp(B) = 1.589). Interpretation Plasma sPD‐1 and sPD‐L1 levels reflected current disease severity and activity, and predicted future relapses in AQP4‐IgG (+) NMOSD, suggesting that they hold the potential to guide timely and targeted treatment. |
| first_indexed | 2024-03-08T02:05:05Z |
| format | Article |
| id | doaj.art-b3109ab6661e40568da1c5de27db1266 |
| institution | Directory Open Access Journal |
| issn | 2328-9503 |
| language | English |
| last_indexed | 2024-03-08T02:05:05Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Clinical and Translational Neurology |
| spelling | doaj.art-b3109ab6661e40568da1c5de27db12662024-02-13T18:30:43ZengWileyAnnals of Clinical and Translational Neurology2328-95032024-02-0111243644910.1002/acn3.51964Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSDJia Liu0Xi Shao1Jingya Fan2Ying Wang3Yuanbo Cao4Guojun Tan5Kazuo Sugimoto6Bin Li7Zhen Jia8Institute for Brain Disorders Beijing University of Chinese Medicine Beijing ChinaDepartment of Neurology The Second Hospital of Hebei Medical University Shijiazhuang ChinaDepartment of Neurology The Second Hospital of Hebei Medical University Shijiazhuang ChinaDepartment of Neurology The Second Hospital of Hebei Medical University Shijiazhuang ChinaDepartment of Neurology The Second Hospital of Hebei Medical University Shijiazhuang ChinaDepartment of Neurology The Second Hospital of Hebei Medical University Shijiazhuang ChinaInstitute for Brain Disorders Beijing University of Chinese Medicine Beijing ChinaDepartment of Neurology The Second Hospital of Hebei Medical University Shijiazhuang ChinaDepartment of Neurology The Second Hospital of Hebei Medical University Shijiazhuang ChinaAbstract Objective Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune‐mediated disorder with aquaporin 4‐immunoglobulin G (AQP4‐IgG) in most settings. Soluble programmed death‐1 (sPD‐1) and soluble programmed death ligand 1 (sPD‐L1) play key roles in immunomodulation. We aim to assess the association of sPD‐1 and sPD‐L1 with cytokines and their clinical significance in AQP4‐IgG (+) NMOSD. Method We measured plasma sPD‐1, sPD‐L1, and 10 cytokines levels of 66 AQP4‐IgG (+) NMOSD patients, including 40 patients in attack (attack‐NMOSD) and 26 patients in remission (remission‐NMOSD) phases, and 28 healthy controls through ultrasensitive Simoa and SP‐X platform, respectively. We also performed >2 years (median) of follow‐up after testing and analyzed the relationship between the detection index and current and future clinical parameters. Result Plasma sPD‐1 level discriminated attack‐NMOSD from remission‐NMOSD (AUC = 0.692, p = 0.009). sPD‐1 and sPD‐L1 levels positively correlated with IL‐6 (rsPD‐1 = 0.313; rsPD‐L1 = 0.508), IFN‐γ (rsPD‐1 = 0.331; rsPD‐L1 = 0.456), and TNF‐α (rsPD‐1 = 0.451; rsPD‐L1 = 0.531) expression, as well as clinical indicators, including the EDSS score (rsPD‐1 = 0.331; rsPD‐L1 = 0.402), number of attacks (rsPD‐1 = 0.431) and segments of spinal cord involvement (rsPD‐1 = 0.462; rsPD‐L1 = 0.508). The risk of relapse within 2 years after sampling was associated with higher sPD‐1/sPD‐L1 ratio in attack‐NMOSD (p = 0.022; Exp(B) = 1.589). Interpretation Plasma sPD‐1 and sPD‐L1 levels reflected current disease severity and activity, and predicted future relapses in AQP4‐IgG (+) NMOSD, suggesting that they hold the potential to guide timely and targeted treatment.https://doi.org/10.1002/acn3.51964 |
| spellingShingle | Jia Liu Xi Shao Jingya Fan Ying Wang Yuanbo Cao Guojun Tan Kazuo Sugimoto Bin Li Zhen Jia Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD Annals of Clinical and Translational Neurology |
| title | Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD |
| title_full | Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD |
| title_fullStr | Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD |
| title_full_unstemmed | Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD |
| title_short | Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD |
| title_sort | association of plasma spd 1 and spd l1 with disease status and future relapse in aqp4 igg nmosd |
| url | https://doi.org/10.1002/acn3.51964 |
| work_keys_str_mv | AT jialiu associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT xishao associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT jingyafan associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT yingwang associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT yuanbocao associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT guojuntan associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT kazuosugimoto associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT binli associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd AT zhenjia associationofplasmaspd1andspdl1withdiseasestatusandfuturerelapseinaqp4iggnmosd |